IL-2
Interleukin-2 (IL-2) is a key cytokine regulating T cell proliferation, differentiation, and survival[1]. Mechanistically, IL-2 signals through the heterotrimeric IL-2 receptor complex, activating the JAK1/3-STAT5 pathway to induce transcription of genes critical for T cell expansion and function[1]. In disease models, IL-2 has been shown to drive regulatory T cell (Treg) expansion, contributing to immune homeostasis and suppression of autoimmunity, while its dysregulation is implicated in cancer and chronic inflammatory conditions[1]. Compared with related γ-chain cytokines, IL-2 exhibits unique receptor specificity and distinct downstream signaling kinetics, leading to selective activation of Tregs versus effector T cells[1]. Experimentally, IL-2 stimulation induces expression and unconventional secretion of IL-32β from T cells, highlighting a functional crosstalk between IL-2 signaling and proinflammatory cytokine networks[1]. Agonists and inhibitors of IL-2 or its receptor have been utilized to manipulate immune responses, providing platforms for preclinical models of autoimmunity, cancer immunotherapy, and T cell functional studies[1]. Therefore, IL-2 serves as both a central immunoregulatory factor and a practical tool for experimental modulation of T cell-mediated immunity[1].
-
IL-2 Related Products (115)
Related Products (115)
-
Recombinant Proteins (22)
-
Casein hydrolysate
0 ImagesCat. No.: HY-126404CAS No.: 65072-00-6Casein hydrolysate is an orally effective, multi-functional mixture of bioactive peptides, a hydrolysis product of casein (HY-125865), containing ACE inhibitors and immunomodulatory target regulators, among others. Casein hydrolysate releases short-chain bioactive peptides through enzymatic hydrolysis of casein, increasing cellular glutathione and catalase levels, enhancing ConA-induced IL-2 production, and exhibiting metal ion chelation, free radical scavenging, antibacterial, and mineral absorption-promoting effects. Casein hydrolysate lowers blood pressure by inhibiting angiotensin-converting enzyme (ACE) and reducing bradykinin degradation.
-
(5Z,2E)-CU-3
0 ImagesCat. No.: HY-121638ACAS No.: 1815598-71-0(5Z,2E)-CU-3 is an isomer of CU-3 (HY-121638). CU-3 is a DGKα inhibitor with an IC50 of 0.6 μM. CU-3 competitively reduces DGKα’s affinity for ATP via binding to the enzyme’s catalytic region. CU-3 induces apoptosis in cancer cells. CU-3 promotes T-cell activation and enhances IL-2 production. CU-3 can be used for the research of hepatocellular carcinoma and cervical cancer.
-
P60-L3-VHL
0 ImagesCat. No.: HY-162943Purity: 99.84%P60-L3-VHL is a PROTAC degrader targeting Foxp3. P60-L3-VHL triggers the ubiquitination modification of Foxp3 by conjugating the Foxp3-targeting peptide P60 with the VHL E3 ubiquitin ligase ligand via a long linker, and mediates protein degradation through the proteasome pathway. P60-L3-VHL blocks the nuclear translocation of Foxp3, relieves the transcriptional inhibition of IL2 and IFN-γ, and inhibits the differentiation of iTreg cells. P60-L3-VHL is applicable to cancer-related research.
-
Sodium chloride, meets analytical specification of Ph. Eur. BP USP, ≤0.00002% Al
0 ImagesSynonyms: Halite, meets analytical specification of Ph. Eur. BP USPSodium chloride, meets analytical specification of Ph. Eur. BP USP, ≤0.00002% Al, an inorganic salt is an orally active salt. Sodium chloride, meets analytical specification of Ph. Eur. BP USP, ≤0.00002% Al, an inorganic salt induces the expression of ATP1A1. Sodium chloride, meets analytical specification of Ph. Eur. BP USP, ≤0.00002% Al, an inorganic salt induces the pro-inflammatory cytokines IL-2, TNFα, IL-9 and several chemokines. Sodium chloride, meets analytical specification of Ph. Eur. BP USP, ≤0.00002% Al, an inorganic salt enhances the anti-tumor activities of Digoxin (HY-B1049) against small cell lung cancer. Sodium chloride, meets analytical specification of Ph. Eur. BP USP, ≤0.00002% Al, an inorganic salt drives autoimmune disease by the induction of pathogenic Th17 cells.
-
Suplatast (Tosilate)
0 ImagesSynonyms: IPD 1151T
-
Ginsenoside F3
0 ImagesGinsenoside F3 is a saponin extracted from the leaves of Panax ginseng with immunoenhancing and antitumor immunostimulatory activities. Ginsenoside F3 upregulates RIPOR2 with a Kd value of 3.77 μM. Ginsenoside F3 enhances NF‑κB activation, upregulates T‑bet and downregulates GATA‑3, increases the production of IL‑2 and IFN‑γ, decreases the production of IL‑4 and IL‑10, reverses CD8⁺ T‑cell exhaustion, restores cytokine secretion, and enhances antitumor immunity in a mouse non‑small cell lung cancer model. Ginsenoside F3 can be used for the research of non-small cell lung cancer.
-
Sec61-IN-3
0 ImagesSec61-IN-3 is a Sec61 inhibitor. Sec61-IN-3 shows a significant inhibitory effect on PD-1 related reporter gene cell models (PD1tsGluc) (IC50 = 42 nM), and also has certain inhibitory activity on Her3 (IC50 = 99 nM), IL2 (IC50 = 144 nM) related reporter pathways, but has a relatively weak inhibitory effect on the TNFα (IC50 = 580 nM) pathway. Sec61-IN-3 can be used for cancer research.
-
Ritlecitinib tosylate
0 ImagesSynonyms: PF-06651600 tosylateRitlecitinib (PF-06651600) tosylate is a highly selective, orally active, irreversible covalent JAK3 inhibitor (IC50=33 nM) without inhibitory activity towards JAK1, JAK2, and TYK2 (IC50 >10 μ M). Ritlecitinib tosylate rapidly inactivates the JAK3 kinase, and blocks signaling and downstream STAT phosphorylation mediated by common gamma chain cytokines such as IL-2 and IL-15. Ritlecitinib tosylate can inhibit Th1/Th17 cell differentiation and function, and effectively suppress preclinical animal models such as alopecia areata, adjuvant-induced arthritis (AIA), and experimental autoimmune encephalomyelitis (EAE).
-
SP4206
0 ImagesCat. No.: HY-119424CAS No.: 515846-21-6SP4206 is an IL-2/IL-2Rα interaction inhibitor. SP4206 binds with high affinity (Kd=70 nM) to IL-2 and blocks binding to its natural receptor IL-2Rα (Kd=10 nM).
-
(R)-Zelebrudomide
0 ImagesSynonyms: (R)-NX-2127(R)-Zelebrudomide ((R)-NX-2127) is an isomer of Zelebrudomide (HY-153220). Zelebrudomide is an orally active BTK-targeting PROTAC degrader, with DC50 values of 4.5 nM and 31 nM against wild-type BTK and BTKC481S mutant, respectively. Zelebrudomide recruits the cereblon E3 ubiquitin ligase complex to mediate the degradation of BTK. Zelebrudomide also acts as a molecular glue to bind the cereblon E3 ubiquitin ligase complex, mediating the degradation of IKZF1 and IKZF3. Zelebrudomide can be used in the research of B-cell malignancies.
-
Patiromer
0 ImagesCat. No.: HY-112961CAS No.: 1208912-84-8Patiromer is an orally active, selective and non-absorbable intestinal potassium (K+) polymer binder that reversibly binds potassium ions in exchange for calcium (Ca2+). Patiromer can rapidly and continuously reduce serum potassium levels, maintain a normal blood potassium state, and reduce serum aldosterone levels. Patiromer also increases fecal potassium excretion. Patiromer is mainly used in the study of hyperkalemia associated with diseases such as chronic kidney disease, diabetes, and heart failure, and is particularly suitable for improving renin-angiotensin-aldosterone system inhibitor (RAASi) therapy.
-
Tucotuzumab celmoleukin
0 ImagesSynonyms: EMD 273066; huKS-IL2Tucotuzumab celmoleukin (EMD 273066) is an immunocytokine. Tucotuzumab celmoleukin consists of the following components: an IgG1 monoclonal antibody targeting human EpCAM antigen, and two molecules of IL2. Tucotuzumab celmoleukin binds to EpCAM. Tucotuzumab celmoleukin exerts anti-tumor effects on colon adenocarcinoma in synergy with radiofrequency ablation. Tucotuzumab celmoleukin can be used in research related to colon adenocarcinoma and colon cancer.
-
GNE-6893
0 ImagesGNE-6893 is an orally active, selective HPK1 inhibitor with a Ki < 0.02 nM. GNE-6893 enhances T cell receptor signaling in primary human T cells. GNE-6893 increases IL2 production in stimulated primary human T cells. GNE-6893 can be used for the research of chronic refractory cancers.
-
M351-0056
0 ImagesM351-0056 is an orally active VISTA agonist with a Kd value of 12.60 μM. M351-0056 inhibits the activation of the JAK2-STAT2 pathway, reduces the phosphorylation levels of JAK2 and STAT2, and regulates type I interferon (IFN-I) and non-canonical NF-κB pathways. M351-0056 decreases the levels of cytokines (IFN-γ, IL-17A, TNF-α, IL-2 and IL-1β). M351-0056 improves imiquimod (HY-B0180)-induced psoriasis-like skin inflammation, reduces autoantibody levels, kidney damage and immune cell expansion in mice susceptible to chronic graft-versus-host disease and lupus, and delays the progression of systemic lupus erythematosus. M351-0056 can be used in research related to psoriasis-like dermatitis and systemic lupus erythematosus.
-
Anti-Mouse IL-2 Antibody (S4B6-1)
0 ImagesCat. No.: HY-P990796Anti-Mouse IL-2 Antibody (S4B6-1) is an anti-mouse IL-2 IgG2a monoclonal antibody. Anti-Mouse IL-2 Antibody (S4B6-1) can reduce CD4+ T cells and increase Tregs. Anti-Mouse IL-2 Antibody (S4B6-1) can induce Th17 cell differentiation. Anti-Mouse IL-2 Antibody (S4B6-1) can be used for research on cancer such as melanoma. The recommend isotype control of Anti-Mouse IL-2 Antibody (S4B6-1): Rat IgG2a kappa, Isotype Control (HY-P990679).
-
Anti-CD19 Antibody (4G7)
0 ImagesCat. No.: HY-P990870Purity: 98%Anti-CD19 Antibody (4G7) is an anti-human CD19 IgG1 monoclonal antibody. Anti-CD19 Antibody (4G7) reduces the killing effect of CAR T cells on Raji cells. Anti-CD19 Antibody (4G7) can be used for research on immunology. Anti-CD19 Antibody (4G7) is often used in flow cytometry. The recommend isotype control of Anti-CD19 Antibody (4G7): Mouse IgG1 kappa, Isotype Control (HY-P99977).
